Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Zymeworks
Company facts
- Status
- NASDAQ ZYME
- Headquarters
- MIDDLETOWN, DE
- Industry
- Pharmaceutical Preparations SIC 2834
- Fiscal year end
- 1231
- Links
- Filings · SEC · Quote · Google
- Source
- SEC
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 76 | 76 | 106 |
| Operating income | −138 | −137 | −93 |
| Net income | −119 | −123 | −81 |
| Total assets | 581 | 463 | 347 |
| Total liabilities | 116 | 124 | 78 |
| Total equity | 465 | 339 | 269 |
Unit: USD million · Consolidated statements · Source SEC 10-K/20-F
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
Pharmaceutical filing citing an Annals of Oncology paper — Zymeworks, 2022-12-19 · Readout case C073
National R&D projects (NTIS)
No records
Korean patent filings (KIPRIS)
No records
Papers with affiliated authors (OpenAlex)
No records
Last updated 2026-09-21